Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.
- Status
- RECRUITING
- Phase
- PHASE4
Clinical Trials Related to Osimertinib
Related studies linked through entity extraction aliases.
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
- Status
- RECRUITING
- Phase
- PHASE2
First in Human Study of AZD9592 in Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Status
- RECRUITING
- Phase
- PHASE2
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- N/A
Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations
- Status
- UNKNOWN
- Phase
- PHASE2
EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
Osimertinib for NSCLC With Uncommon EGFR Mutations
- Status
- SUSPENDED
- Phase
- N/A
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
- Status
- RECRUITING
- Phase
- PHASE3
Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
- Status
- RECRUITING
- Phase
- PHASE2
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC
- Status
- TERMINATED
- Phase
- PHASE2
Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1